|Day Low/High||170.25 / 172.83|
|52 Wk Low/High||127.10 / 213.27|
The potential transaction could be a true game-changer that makes sense strategically and financially, albeit dilutive near term.
Thermo Fisher Scientific (TMO) has reportedly offered $30 billion to acquire Illumina (ILMN).
Illumina, Inc. (NASDAQ: ILMN) and FlowJo, LLC, today announced a partnership to develop and co-market analysis software for single cell next-generation sequencing (NGS) data.
Lots of energy names facing the potential for lower prices.
Illumina is in breakout mode and could be headed much higher.
Illumina, Inc. (NASDAQ: ILMN) announced today that Philip W.
The most recent short interest data has been released for the 07/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Trade-Ideas LLC identified Illumina (ILMN) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Trade-Ideas LLC identified Illumina (ILMN) as a post-market leader candidate
Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the second quarter of fiscal year 2016.
TheStreet highlights 3 stocks pushing the drugs industry lower today.
Stocks with insider trader activity include AFSI, ILMN and SIG
TheStreet highlights 3 stocks pushing the health care sector lower today.
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2016 following the close of market on Tuesday, July 26, 2016.
Illumina, Inc. (NASDAQ: ILMN) today announced that it supports the Food and Drug Administration (FDA) in their efforts to provide a flexible and streamlined approach to the oversight of next generation sequencing (NGS)...
Trade-Ideas LLC identified Illumina (ILMN) as an unusual social activity candidate
Illumina (ILMN) stock is falling on Tuesday morning after Morgan Stanley cut its rating on shares to ‘underweight’ from ‘equal weight.’
Here are Tuesday's top research calls, including upgrades for CyberArk Software and Nordstrom, and downgrades for Netflix and Skyworks Solutions.
Cramer says you're in good shape with Dominion Resources, but he is avoiding Freeport-McMoRan.
Cramer takes Thor over Polaris and can't wait for Danaher to split.
There's been so much news coverage about whether the United Kingdom will leave the European Union that it's making us numb, Cramer says.
Ever hear of space congestion, Bots or liquid biopsy? The phrases are part of a group of 21 investment buzzwords identified by Goldman Sachs in its annual buzzword report.
These five companies could turn out to be wonderful longer-term investments, but right now their charts are not attractive.
Three market-beating mutual fund managers discussed their favorite stocks at the Morningstar Investment Conference this week in Chicago.
Illumina, Inc. (NASDAQ: ILMN) today announced that it has signed deals with 12 customers for its new Infinium® Global Screening Array (GSA).
Shares of Veracyte are sliding after the Centers for Medicare and Medicaid Services, or CMS, proposed a reimbursement rate reduction on the company's Afirma GEC diagnostic test.
Concerned about the market's volatility? Here's a time-tested strategy that leverages risk for market-thumping gains.
Cramer is avoiding Hertz and takes Thermo Fisher over Illumina.